Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening - Scorecard - MDSpire

Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening

  • By

  • Caitlin Kotian

  • Arshum Mirzaeifard

  • Elsa Wani

  • Karen Hock

  • Katherine Ashworth

  • Lindsey Sova

  • Roman Skoracki

  • Ann Scheck McAlearney

  • Electra D. Paskett

  • Tari King

  • Sara P. Myers

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Insights from Healthcare Professionals on the Adoption of Prospective Screening for Lymphedema Associated with Breast Cancer

At a Glance

CategoryDetail
Condition
Key MechanismsProspective surveillance models (PSMs) including presurgical baseline assessments and postoperative longitudinal limb measurement and symptom monitoring.
Target Population
Care Setting

Key Highlights

  • BCRL affects 2% to 60% of breast cancer patients.
  • Barriers to PSM implementation include clinician knowledge gaps and patient understanding.

Guideline-Based Recommendations

Diagnosis

  • Conduct presurgical baseline assessments for BCRL.

Management

  • Implement frequent postoperative screening appointments at 6 months, then every 6 months for 2 years, and annually thereafter.

Monitoring & Follow-up

  • Utilize patient-reported outcomes (PROs) in clinical workflows.

Risks

    Patient & Prescribing Data

    Breast cancer survivors undergoing treatment.

    Clinical Best Practices

      Related Resources & Content

      Original Source(s)

      Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening

      • by Caitlin Kotian, Arshum Mirzaeifard, Elsa Wani, Karen Hock, Katherine Ashworth, Lindsey Sova, Roman Skoracki, Ann Scheck McAlearney, Electra D. Paskett, Tari King, Sara P. Myers

      • May 28, 2026

      Related Content

      Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report

      Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells

      When should you get a mammogram? Conflicting advice makes it hard to know